Login to Your Account

Xenoport drug hits phase II psoriasis endpoints but dinged on diarrhea

By Marie Powers
News Editor

Tuesday, September 15, 2015
A pre-market lift for shares of Xenoport Inc. (NASDAQ:XNPT) quickly deflated Tuesday following release of preliminary top-line results from the phase II trial of XP23829 in moderate to severe chronic plaque-type psoriasis.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription